Closure by iptakalim, a cardiovascular KATP channel opener, of rat pancreatic β-cell KATP channels and its molecular basis

Makoto Wakui, Naoko Misaki, Sechiko Suga, Xia Mao, Yu-Fung Lin, Jie Wu

Research output: Contribution to journalArticle

Abstract

Diabetes mellitus is a group of diseases characterized by high levels of blood glucose resulting from defects in insulin production, insulin action, or both. Diabetes patients usually have accompanying cardiovascular disorders. Sulfonylureas have been the leading oral antihyperglycemic agents for type 2 diabetes treatment, which currently still constitute the most popular anti-diabetic drugs. Nevertheless, concern has arisen over the side effects of sulfonylureas on the cardiovascular system. Here we report that iptakalim, a novel cardiovascular ATP-sensitive potassium (KATP) channel opener, closed rat pancreatic β-cell KATP channels and increased insulin release. Using whole-cell patch-clamp recordings, iptakalim depolarized β-cells, induced action potential firing and reduced pancreatic K ATP channel currents. Using single-channel recordings, iptakalim reduced KATP channel open-probability independently of intracellular ATP concentrations. We demonstrated that iptakalim elevated intracellular Ca2+ concentrations and increased insulin release as revealed by fluorescence imaging (fura-2) and biochemical measurements, respectively. In addition, iptakalim significantly inhibited the open-probability of recombinant Kir6.2/SUR1 and Kir6.2FL4A (a trafficking mutant of the Kir6.2) channels expressed in transfected human embryonic kidney (HEK) 293 cells. Collectively, iptakalim, a cardiovascular KATP channel opener, closes rat pancreatic β-cell KATP channels, which may result from direct inhibition of the Kir6.2 subunit. Therefore, iptakalim bi-directionally regulates KATP channels in cardiovascular and pancreatic tissues, and this unique pharmacological property suggests iptakalim could be used as a new therapeutic strategy for the treatment of type 2 diabetes with the potential benefit in alleviating cardiac and/or vascular disorders frequently associated with diabetes.

Original languageEnglish (US)
JournalHirosaki Medical Journal
Volume59
Issue numberSUPPL.
StatePublished - 2007
Externally publishedYes

Fingerprint

KATP Channels
Insulin
Type 2 Diabetes Mellitus
Adenosine Triphosphate
N-(1-methylethyl)-1,1,2-trimethylpropylamine
Fura-2
Optical Imaging
Cardiovascular System
Hypoglycemic Agents
Action Potentials
Blood Vessels
Blood Glucose
Diabetes Mellitus
Therapeutics
Pharmacology
Kidney

Keywords

  • Insulin secretion
  • Iptakalim
  • Islet β-cell
  • K channel
  • Kir6.2

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Closure by iptakalim, a cardiovascular KATP channel opener, of rat pancreatic β-cell KATP channels and its molecular basis. / Wakui, Makoto; Misaki, Naoko; Suga, Sechiko; Mao, Xia; Lin, Yu-Fung; Wu, Jie.

In: Hirosaki Medical Journal, Vol. 59, No. SUPPL., 2007.

Research output: Contribution to journalArticle

@article{453d080ebb5846beaa70d266a6fe1f94,
title = "Closure by iptakalim, a cardiovascular KATP channel opener, of rat pancreatic β-cell KATP channels and its molecular basis",
abstract = "Diabetes mellitus is a group of diseases characterized by high levels of blood glucose resulting from defects in insulin production, insulin action, or both. Diabetes patients usually have accompanying cardiovascular disorders. Sulfonylureas have been the leading oral antihyperglycemic agents for type 2 diabetes treatment, which currently still constitute the most popular anti-diabetic drugs. Nevertheless, concern has arisen over the side effects of sulfonylureas on the cardiovascular system. Here we report that iptakalim, a novel cardiovascular ATP-sensitive potassium (KATP) channel opener, closed rat pancreatic β-cell KATP channels and increased insulin release. Using whole-cell patch-clamp recordings, iptakalim depolarized β-cells, induced action potential firing and reduced pancreatic K ATP channel currents. Using single-channel recordings, iptakalim reduced KATP channel open-probability independently of intracellular ATP concentrations. We demonstrated that iptakalim elevated intracellular Ca2+ concentrations and increased insulin release as revealed by fluorescence imaging (fura-2) and biochemical measurements, respectively. In addition, iptakalim significantly inhibited the open-probability of recombinant Kir6.2/SUR1 and Kir6.2FL4A (a trafficking mutant of the Kir6.2) channels expressed in transfected human embryonic kidney (HEK) 293 cells. Collectively, iptakalim, a cardiovascular KATP channel opener, closes rat pancreatic β-cell KATP channels, which may result from direct inhibition of the Kir6.2 subunit. Therefore, iptakalim bi-directionally regulates KATP channels in cardiovascular and pancreatic tissues, and this unique pharmacological property suggests iptakalim could be used as a new therapeutic strategy for the treatment of type 2 diabetes with the potential benefit in alleviating cardiac and/or vascular disorders frequently associated with diabetes.",
keywords = "Insulin secretion, Iptakalim, Islet β-cell, K channel, Kir6.2",
author = "Makoto Wakui and Naoko Misaki and Sechiko Suga and Xia Mao and Yu-Fung Lin and Jie Wu",
year = "2007",
language = "English (US)",
volume = "59",
journal = "Hirosaki Medical Journal",
issn = "0439-1721",
publisher = "Hirosaki University School of Medicine",
number = "SUPPL.",

}

TY - JOUR

T1 - Closure by iptakalim, a cardiovascular KATP channel opener, of rat pancreatic β-cell KATP channels and its molecular basis

AU - Wakui, Makoto

AU - Misaki, Naoko

AU - Suga, Sechiko

AU - Mao, Xia

AU - Lin, Yu-Fung

AU - Wu, Jie

PY - 2007

Y1 - 2007

N2 - Diabetes mellitus is a group of diseases characterized by high levels of blood glucose resulting from defects in insulin production, insulin action, or both. Diabetes patients usually have accompanying cardiovascular disorders. Sulfonylureas have been the leading oral antihyperglycemic agents for type 2 diabetes treatment, which currently still constitute the most popular anti-diabetic drugs. Nevertheless, concern has arisen over the side effects of sulfonylureas on the cardiovascular system. Here we report that iptakalim, a novel cardiovascular ATP-sensitive potassium (KATP) channel opener, closed rat pancreatic β-cell KATP channels and increased insulin release. Using whole-cell patch-clamp recordings, iptakalim depolarized β-cells, induced action potential firing and reduced pancreatic K ATP channel currents. Using single-channel recordings, iptakalim reduced KATP channel open-probability independently of intracellular ATP concentrations. We demonstrated that iptakalim elevated intracellular Ca2+ concentrations and increased insulin release as revealed by fluorescence imaging (fura-2) and biochemical measurements, respectively. In addition, iptakalim significantly inhibited the open-probability of recombinant Kir6.2/SUR1 and Kir6.2FL4A (a trafficking mutant of the Kir6.2) channels expressed in transfected human embryonic kidney (HEK) 293 cells. Collectively, iptakalim, a cardiovascular KATP channel opener, closes rat pancreatic β-cell KATP channels, which may result from direct inhibition of the Kir6.2 subunit. Therefore, iptakalim bi-directionally regulates KATP channels in cardiovascular and pancreatic tissues, and this unique pharmacological property suggests iptakalim could be used as a new therapeutic strategy for the treatment of type 2 diabetes with the potential benefit in alleviating cardiac and/or vascular disorders frequently associated with diabetes.

AB - Diabetes mellitus is a group of diseases characterized by high levels of blood glucose resulting from defects in insulin production, insulin action, or both. Diabetes patients usually have accompanying cardiovascular disorders. Sulfonylureas have been the leading oral antihyperglycemic agents for type 2 diabetes treatment, which currently still constitute the most popular anti-diabetic drugs. Nevertheless, concern has arisen over the side effects of sulfonylureas on the cardiovascular system. Here we report that iptakalim, a novel cardiovascular ATP-sensitive potassium (KATP) channel opener, closed rat pancreatic β-cell KATP channels and increased insulin release. Using whole-cell patch-clamp recordings, iptakalim depolarized β-cells, induced action potential firing and reduced pancreatic K ATP channel currents. Using single-channel recordings, iptakalim reduced KATP channel open-probability independently of intracellular ATP concentrations. We demonstrated that iptakalim elevated intracellular Ca2+ concentrations and increased insulin release as revealed by fluorescence imaging (fura-2) and biochemical measurements, respectively. In addition, iptakalim significantly inhibited the open-probability of recombinant Kir6.2/SUR1 and Kir6.2FL4A (a trafficking mutant of the Kir6.2) channels expressed in transfected human embryonic kidney (HEK) 293 cells. Collectively, iptakalim, a cardiovascular KATP channel opener, closes rat pancreatic β-cell KATP channels, which may result from direct inhibition of the Kir6.2 subunit. Therefore, iptakalim bi-directionally regulates KATP channels in cardiovascular and pancreatic tissues, and this unique pharmacological property suggests iptakalim could be used as a new therapeutic strategy for the treatment of type 2 diabetes with the potential benefit in alleviating cardiac and/or vascular disorders frequently associated with diabetes.

KW - Insulin secretion

KW - Iptakalim

KW - Islet β-cell

KW - K channel

KW - Kir6.2

UR - http://www.scopus.com/inward/record.url?scp=38049055718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38049055718&partnerID=8YFLogxK

M3 - Article

VL - 59

JO - Hirosaki Medical Journal

JF - Hirosaki Medical Journal

SN - 0439-1721

IS - SUPPL.

ER -